• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PLATINUM Drug Record

  • Summary
  • Interactions
  • Claims
  • PLATINUM chembl:CHEMBL1235478

    Alternate Names:

    PLATINUM

    Drug Info:

    (0 More Sources)

    Publications:

    Samimi et al., 2003, Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients., Clin. Cancer Res.
    Samimi et al., 2004, Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B., Mol. Pharmacol.
    Bokemeyer et al., 1993, A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours., Eur. J. Cancer
    Marsh et al., 2007, Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer., J. Clin. Oncol.
    Levresse et al., 2002, Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells., Mol. Pharmacol.
    Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
    Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
    Tibaldi C et al., 2008, Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
    Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics
    Sullivan I et al., 2014, Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy., Cancer Lett
    Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
    Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
    Kalikaki A et al., 2009, DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer., Clin Lung Cancer
    Pérez-Ramírez C et al., 2016, Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients., Pharmacol Res
    Zucali PA et al., 2011, Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin., Clin Cancer Res
    Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
    Yan L et al., 2012, Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy., Pharmacogenomics
    Joerger M et al., 2015, Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy., Cancer Chemother Pharmacol
    De Mattia E et al., 2016, Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine., Pharmacogenomics
    Caiola E et al., 2013, DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer., Pharmacogenomics J
    Yin JY et al., 2016, Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine., Pharmacogenomics
    Caronia et al., 2009, Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients., Pharmacogenomics J.
    Lamas MJ et al., 2011, Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer., Pharmacogenomics
    Delmastro et al., 1997, DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines., Cancer Chemother. Pharmacol.
  • PLATINUM   ERCC5

    Interaction Score: 8.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22158331


    Sources:
    PharmGKB

  • PLATINUM   KLC3

    Interaction Score: 6.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19434073 22188361 29662106 22026922 21449681


    Sources:
    PharmGKB

  • PLATINUM   HNF1B

    Interaction Score: 4.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27561454


    Sources:
    PharmGKB

  • PLATINUM   ERCC1

    Interaction Score: 3.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19786980 22188361 18347182 21902499 25069034 21057378 29662106 19362955 27498158 21262916 22026922 22329723


    Sources:
    PharmGKB

  • PLATINUM   ERCC2

    Interaction Score: 2.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19434073 22188361 29662106 22026922 21449681


    Sources:
    PharmGKB

  • PLATINUM   ATP7A

    Interaction Score: 2.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14676106 15213293


    Sources:
    NCI

  • PLATINUM   ATP7B

    Interaction Score: 1.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15213293


    Sources:
    NCI

  • PLATINUM   XRCC1

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17925548


    Sources:
    NCI

  • PLATINUM   TYMSOS

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25677447


    Sources:
    PharmGKB

  • PLATINUM   DDIT3

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8996528


    Sources:
    NCI

  • PLATINUM   CSF2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8110490


    Sources:
    NCI

  • PLATINUM   TYMS

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25677447


    Sources:
    PharmGKB

  • PLATINUM   MAPK8

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12181446


    Sources:
    NCI

  • PLATINUM   GSTP1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27462924


    Sources:
    PharmGKB

  • NCI: PLATINUM

    • Version: 14-September-2017

    Alternate Names:
    C376 NCI drug code

    Drug Info:

    Publications:
    Samimi et al., 2003, Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients., Clin. Cancer Res.
    Samimi et al., 2004, Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B., Mol. Pharmacol.
    Marsh et al., 2007, Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer., J. Clin. Oncol.

  • PharmGKB: platinum

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Joerger M et al., 2015, Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy., Cancer Chemother Pharmacol
    Yin JY et al., 2016, Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine., Pharmacogenomics
    Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J

  • ChemblDrugs: chembl:CHEMBL1235478

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21